- Home
- FCT vs PBYI Comparison
FCT vs PBYI Comparison
Compare FCT & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCT | PBYI |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.6M | 263.4M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | FCT | PBYI |
|---|---|---|
| Price | $9.77 | $6.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 102.7K | ★ 432.8K |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | ★ 11.29% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.61 |
| Revenue | N/A | ★ $27,685,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $10.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.61 | $2.58 |
| 52 Week High | $10.30 | $7.68 |
Technical Indicators
Market Signals| Indicator | FCT | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 44.18 | 45.04 |
| Support Level | $9.59 | $5.57 |
| Resistance Level | $10.04 | $6.15 |
| Average True Range (ATR) | 0.08 | 0.38 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 45.65 | 27.98 |
Price Performance
Historical ComparisonAbout FCT First Trust Senior Floating Rate Income Fund II of Beneficial Interest
First Trust Senior Floating Rate Income Fund II is a United States-based diversified, closed-end management investment company. Its investment objective is to seek a high level of current income. As a secondary objective, it attempts to preserve capital. The fund invests in a portfolio of senior secured floating-rate corporate loans (Senior Loans) of companies from different industries, such as Insurance, Software, Health Care Providers and Services, Professional Services, Health Care Technology, IT Services, and others.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.